VitaSpring Biomedical Co. Ltd. (VSBC)
OTCMKTS · Delayed Price · Currency is USD
0.0111
-0.2390 (-95.56%)
At close: Feb 12, 2026
VitaSpring Biomedical Balance Sheet
Financials in millions USD. Fiscal year is February - January.
Millions USD. Fiscal year is Feb - Jan.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jan '26 Jan 31, 2026 | Jan '25 Jan 31, 2025 | Jan '24 Jan 31, 2024 | Jan '23 Jan 31, 2023 | Jan '22 Jan 31, 2022 |
Cash & Equivalents | 0.01 | 0 | 0 | 0 | 0.03 | 0.11 |
Short-Term Investments | - | - | - | 0.02 | - | - |
Cash & Short-Term Investments | 0.01 | 0 | 0 | 0.02 | 0.03 | 0.11 |
Cash Growth | - | 666.18% | -98.85% | -20.33% | -72.34% | 136.16% |
Receivables | - | - | - | - | 0.38 | 2.95 |
Prepaid Expenses | 0 | 0.01 | - | - | 0.03 | 0 |
Total Current Assets | 0.01 | 0.01 | 0 | 0.02 | 0.44 | 3.06 |
Property, Plant & Equipment | 0 | 0 | 0.01 | 0.11 | 0.31 | 0.52 |
Other Long-Term Assets | - | - | - | - | 0.02 | 0.02 |
Total Assets | 0.01 | 0.01 | 0.01 | 0.14 | 0.77 | 3.6 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jan '26 Jan 31, 2026 | Jan '25 Jan 31, 2025 | Jan '24 Jan 31, 2024 | Jan '23 Jan 31, 2023 | Jan '22 Jan 31, 2022 |
Accounts Payable | 3.12 | 3.06 | 2.91 | 2.75 | 2.47 | 1.25 |
Current Portion of Leases | - | - | - | 0.09 | 0.17 | 0.18 |
Current Income Taxes Payable | 0.34 | 0.34 | 0.31 | 0.22 | 0.22 | 0.21 |
Other Current Liabilities | 1.05 | 1.04 | 0.81 | 0.43 | 0.21 | 0.09 |
Total Current Liabilities | 4.52 | 4.45 | 4.03 | 3.49 | 3.07 | 1.74 |
Long-Term Leases | - | - | - | - | 0.09 | 0.28 |
Long-Term Deferred Tax Liabilities | - | - | - | - | - | 0.01 |
Total Liabilities | 4.52 | 4.45 | 4.03 | 3.49 | 3.16 | 2.03 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jan '26 Jan 31, 2026 | Jan '25 Jan 31, 2025 | Jan '24 Jan 31, 2024 | Jan '23 Jan 31, 2023 | Jan '22 Jan 31, 2022 |
Common Stock | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
Additional Paid-In Capital | 1.25 | 1.25 | 1.25 | 1.14 | 0.97 | 0.78 |
Retained Earnings | -5.77 | -5.7 | -5.28 | -4.51 | -3.39 | 0.78 |
Shareholders' Equity | -4.51 | -4.43 | -4.02 | -3.35 | -2.4 | 1.58 |
Total Liabilities & Equity | 0.01 | 0.01 | 0.01 | 0.14 | 0.77 | 3.6 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 30, 2026 | Jan '26 Jan 31, 2026 | Jan '25 Jan 31, 2025 | Jan '24 Jan 31, 2024 | Jan '23 Jan 31, 2023 | Jan '22 Jan 31, 2022 |
Total Debt | - | - | - | 0.09 | 0.26 | 0.46 |
Net Cash (Debt) | 0.01 | 0 | 0 | -0.07 | -0.23 | -0.36 |
Net Cash Growth | - | 666.18% | - | - | - | - |
Net Cash Per Share | 0.00 | 0.00 | - | -0.00 | -0.00 | -0.00 |
Filing Date Shares Outstanding | 207.03 | 207.03 | 207.03 | 207.03 | 207.03 | 206.52 |
Total Common Shares Outstanding | 207.03 | 207.03 | 207.03 | 207.03 | 207.03 | 206.52 |
Working Capital | -4.51 | -4.43 | -4.03 | -3.46 | -2.63 | 1.32 |
Book Value Per Share | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 | 0.01 |
Tangible Book Value | -4.51 | -4.43 | -4.02 | -3.35 | -2.4 | 1.58 |
Tangible Book Value Per Share | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 | 0.01 |
Machinery | 0.06 | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 |